Clinical Trial Update: Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing vinorelbine plus everolimus to vinorelbine alone as second-line treatment in Her2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Afinitor (everolimus)
• Navelbine (vinorelbine)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer | Phase 2 | Status: COMPLETED